Would you like to be notified of the latest news and updates on the stock market?
Jefferies initiates buy on Krystal Biotech with a $245 price target, citing Vyjuvek's strong growth potential and proprietary ...
Fintel reports that on March 5, 2025, Jefferies initiated coverage of Krystal Biotech (NasdaqGS:KRYS) with a Buy ...
Jefferies analyst Roger Song initiated coverage of Krystal Biotech (KRYS) with a Buy rating and $245 price target Krystal is a commercial ...
Russia plans to increase procurements of drugs against rare diseases despite the current tough business environment and ...
According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 12.98%, which ...
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
Hosted on MSN2d
LGND: First Steps into Cell & Gene TherapyLGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational ...
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Krystal Biotech (KRYS – Research Report) and ...
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended three novel medicines for approval at its ...
NasdaqGS:KRYS Earnings and Revenue History February 28th 2025 A Closer Look At Krystal Biotech's Earnings. In high finance, the key ratio used to measure how well a company conver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback